Skip to main content

In Vitro Antifungal Susceptibility of Oral Candida Isolates from Patients Suffering from Caries and Chronic Periodontitis

Abstract

Caries and chronic periodontitis are common oral diseases where a higher Candida colonization is reported. Antifungal agents could be adjuvant drugs for the therapy of both clinical conditions. The aim of the current study has been to evaluate the in vitro activities of conventional and new antifungal drugs against oral Candida isolates from patients suffering from caries and/or chronic periodontitis. In vitro activities of amphotericin B, fluconazole, itraconazole, miconazole, nystatin, posaconazole and voriconazole against 126 oral Candida isolates (75 Candida albicans, 18 Candida parapsilosis, 11 Candida dubliniensis, six Candida guilliermondii, five Candida lipolytica, five Candida glabrata, four Candida tropicalis and two Candida krusei) from 61 patients were tested by the CLSI M27-A3 method. Most antifungal drugs were highly active, and resistance was observed in less than 5% of tested isolates. Miconazole was the most active antifungal drug, being more than 98% of isolates susceptible. Fluconazole, itraconazole, and the new triazoles, posaconazole and voriconazole, were also very active. Miconazole, fluconazole and voriconazole have excellent in vitro activities against all Candida isolates and could represent suitable treatment for a hypothetically adjunctive therapy of caries and chronic periodontitis.

This is a preview of subscription content, access via your institution.

References

  1. Metwalli KH, Khan SA, Krom BP, Jabra-Rizk MA. Streptococcus mutans, Candida albicans, and the human mouth: a sticky situation. PLoS Pathog. 2013;9:e1003616.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Gangula P, Ravella K, Chukkapalli S. Polybacterial periodontal pathogens alter vascular and gut BH4/nNOS/NRF2-phase II enzyme expression. PLoS One. 2015;10:e0129885.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Yang F, Zeng X, Ning K. Saliva microbiomes distinguish caries-active from healthy human populations. ISME J. 2012;6:1–10.

    Article  PubMed  Google Scholar 

  4. Ge X, Rodriguez R, Trinh M, Gunsolley J, Xu P. Oral microbiome of deep and shallow dental pockets in chronic periodontitis. PLoS One. 2013;8:e65520.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  5. Krom BP, Kidwai S, Ten Cate JM. Candida and other fungal species: forgotten players of healthy oral microbiota. J Dent Res. 2014;93:445–51.

    CAS  Article  PubMed  Google Scholar 

  6. Raja M, Hannan A, Ali K. Association of oral candidal carriage with dental caries in children. Caries Res. 2010;44:272–6.

    CAS  Article  PubMed  Google Scholar 

  7. De-la-Torre J, Marichalar-Mendia X, Varona-Barquin A, Marcos-Arias C, Eraso E, Aguirre-Urizar JM, Quindós G. Caries and Candida colonisation in adult patients in Basque Country (Spain). Mycoses. 2016;59:234–40.

    Article  Google Scholar 

  8. Meurman JH, Parnanen P, Seneviratne CJ, Samaranayake LP, Saarinen AM, Kari K. Prevalence and antifungal drug sensitivity of non-albicans Candida in oral rinse samples of self-caring elderly. Gerodontology. 2011;28:246–52.

    Article  PubMed  Google Scholar 

  9. Urzua B, Hermosilla G, Gamonal J. Yeast diversity in the oral microbiota of subjects with periodontitis: Candida albicans and Candida dubliniensis colonize the periodontal pockets. Med Mycol. 2008;46:783–93.

    CAS  Article  PubMed  Google Scholar 

  10. Zijnge V, van Leeuwen MB, Degener JE. Oral biofilm architecture on natural teeth. PLoS One. 2010;5:e9321.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Sardi JC, Duque C, Mariano FS, Marques MR, Hofling JF, Goncalves RB. Adhesion and invasion of Candida albicans from periodontal pockets of patients with chronic periodontitis and diabetes to gingival human fibroblasts. Med Mycol. 2012;50:43–9.

    CAS  Article  PubMed  Google Scholar 

  12. Sardi JC, Duque C, Mariano FS, Peixoto IT, Hofling JF, Goncalves RB. Candida spp. in periodontal disease: a brief review. J Oral Sci. 2010;52:177–85.

    CAS  Article  PubMed  Google Scholar 

  13. Sardi JC, Almeida AM, Mendes Giannini MJ. New antimicrobial therapies used against fungi present in subgingival sites–a brief review. Arch Oral Biol. 2011;56:951–9.

    CAS  Article  PubMed  Google Scholar 

  14. Williams DW, Lewis MA. Isolation and identification of Candida from the oral cavity. Oral Dis. 2000;6:3–11.

    CAS  Article  PubMed  Google Scholar 

  15. Byadarahally Raju S, Rajappa S. Isolation and identification of Candida from the oral cavity. ISRN Dent. 2011;2011:487921.

    PubMed  PubMed Central  Google Scholar 

  16. Premkumar J, Ramani P, Chandrasekar T, Natesan A, Premkumar P. Detection of species diversity in oral Candida colonization and anti-fungal susceptibility among non-oral habit adult diabetic patients. J Nat Sci Biol Med. 2014;5:148–54.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Matic Petrovic S, Cimbaljevic M, Radunovic M, Kuzmanovic Pficer J, Jotic A, Pucar A. Detection and sampling methods for isolation of Candida spp. from oral cavities in diabetics and non-diabetics. Braz Oral Res. 2015;. doi:10.1590/1807-3107BOR-2015.vol29.0077.

    PubMed  Google Scholar 

  18. Eraso E, Moragues MD, Villar-Vidal M, Sahand IH, González-Gómez N, Pontón J, Quindós G. Evaluation of the new chromogenic medium Candida ID 2 for isolation and identification of Candida albicans and other medically important Candida species. J Clin Microbiol. 2006;44:3340–5.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Romeo O, Criseo G. First molecular method for discriminating between Candida africana, Candida albicans, and Candida dubliniensis by using hwp1 gene. Diagn Microbiol Infect Dis. 2008;62:230–3.

    CAS  Article  PubMed  Google Scholar 

  20. Pravin Charles MV, Kali A, Joseph NM. Performance of chromogenic media for Candida in rapid presumptive identification of Candida species from clinical materials. Pharmacogn Res. 2015;7(Suppl 1):S69–73.

    CAS  Google Scholar 

  21. Blignaut E, van Heerden WF. Molecular and histological association between Candida albicans from oral soft tissue and carious dentine of HIV-positive children. Mycopathologia. 2015;180:193–201.

    CAS  Article  PubMed  Google Scholar 

  22. Bravo Pérez M, Casals Peidró E, Cortés Marticorena FJ, Llodra Calvo JC. Encuesta de salud oral en España 2005. RCOE. 2006;11:409–56.

    Google Scholar 

  23. Becker T, Levin L, Shochat T, Einy S. How much does the DMFT index underestimate the need for restorative care? J Dent Educ. 2007;71:677–81.

    PubMed  Google Scholar 

  24. Jiang Q, Yu M, Min Z, Yi A, Chen D, Zhang Q. AP-PCR detection of Streptococcus mutans and Streptococcus sobrinus in caries-free and caries-active subjects. Mol Cell Biochem. 2012;365:159–64.

    CAS  Article  PubMed  Google Scholar 

  25. Kassebaum NJ, Bernabe E, Dahiya M, Bhandari B, Murray CJ, Marcenes W. Global burden of untreated caries: a systematic review and metaregression. J Dent Res. 2015;94:650–8.

    CAS  Article  PubMed  Google Scholar 

  26. Savage A, Eaton KA, Moles DR, Needleman I. A systematic review of definitions of periodontitis and methods that have been used to identify this disease. J Clin Periodontol. 2009;36:458–67.

    Article  PubMed  Google Scholar 

  27. Canabarro A, Valle C, Farias MR, Santos FB, Lazera M, Wanke B. Association of subgingival colonization of Candida albicans and other yeasts with severity of chronic periodontitis. J Periodontal Res. 2013;48:428–32.

    CAS  Article  PubMed  Google Scholar 

  28. Holtfreter B, Albandar JM, Dietrich T. Standards for reporting chronic periodontitis prevalence and severity in epidemiologic studies: Proposed standards from the joint EU/USA periodontal epidemiology working group. J Clin Periodontol. 2015;42:407–12.

    Article  PubMed  Google Scholar 

  29. Smiley CJ, Tracy SL, Abt E, Michalowicz BS, John MT, Gunsolley J, Cobb CM, Rossmann J, Harrel SK, Forrest JL, Hujoel PP, Noraian KW, Greenwell H, Frantsve-Hawley J, Estrich C, Hanson N. Evidence-based clinical practice guideline on the nonsurgical treatment of chronic periodontitis by means of scaling and root planing with or without adjuncts. J Am Dent Assoc. 2015;146:525–35.

    Article  PubMed  Google Scholar 

  30. Clinical and Laboratory Standards Institute. Clinical and laboratory standards institute. reference method for broth dilution antifungal susceptibility testing for years; approved standard, 3rd ed. CLSI document M27-S3. 2008.

  31. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing for yeasts, fourth informational supplement. CLSI document M27-S4. 2012.

  32. Pfaller MA, Messer SA, Jones RN, Castanheira M. Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010–2012). J Antibiot. 2015;68:556–61.

    CAS  Article  PubMed  Google Scholar 

  33. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:e1–50.

    Article  PubMed  Google Scholar 

  34. Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol. 2012;50:2846–56.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  35. Sanchez Vargas LO, Eraso E, Carrillo-Munoz AJ, Aguirre JM, Gaitan-Cepeda LA, Quindos G. In vitro activity of voriconazole against Mexican oral yeast isolates. Mycoses. 2010;53:200–3.

    Article  PubMed  Google Scholar 

  36. Patil S, Rao RS, Majumdar B, Anil S. Clinical appearance of oral Candida infection and therapeutic strategies. Front Microbiol. 2015;6:1391.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Waltimo TM, Orstavik D, Meurman JH, Samaranayake LP, Haapasalo MP. In vitro susceptibility of Candida albicans isolates from apical and marginal periodontitis to common antifungal agents. Oral Microbiol Immunol. 2000;15:245–8.

    CAS  Article  PubMed  Google Scholar 

  38. Kamikawa Y, Mori Y, Nagayama T. Frequency of clinically isolated strains of oral Candida species at Kagoshima University Hospital, Japan, and their susceptibility to antifungal drugs in 2006–2007 and 2012–2013. BMC Oral Health. 2014;14:14-6831-14-14.

    Article  Google Scholar 

  39. Isham N, Ghannoum MA. Antifungal activity of miconazole against recent Candida strains. Mycoses. 2010;53:434–7.

    CAS  Article  PubMed  Google Scholar 

  40. Rautemaa R, Ramage G. Oral candidosis–clinical challenges of a biofilm disease. Crit Rev Microbiol. 2011;37:328–36.

    CAS  Article  PubMed  Google Scholar 

  41. Bensadoun RJ, Daoud J, El Gueddari B. Comparison of the efficacy and safety of miconazole 50-mg mucoadhesive buccal tablets with miconazole 500-mg gel in the treatment of oropharyngeal candidiasis: a prospective, randomized, single-blind, multicenter, comparative, phase III trial in patients treated with radiotherapy for head and neck cancer. Cancer. 2008;112:204–11.

    CAS  Article  PubMed  Google Scholar 

  42. Collins CD, Cookinham S, Smith J. Management of oropharyngeal candidiasis with localized oral miconazole therapy: efficacy, safety, and patient acceptability. Patient Prefer Adherence. 2011;5:369–74.

    Article  PubMed  PubMed Central  Google Scholar 

  43. De Cremer K, Lanckacker E, Cools TL. Artemisinins, new miconazole potentiators resulting in increased activity against Candida albicans biofilms. Antimicrob Agents Chemother. 2015;59:421–6.

    Article  PubMed  Google Scholar 

  44. Aljaeid BM, Hosny KM. Miconazole-loaded solid lipid nanoparticles: Formulation and evaluation of a novel formula with high bioavailability and antifungal activity. Int J Nanomed. 2016;11:441–7.

    CAS  Article  Google Scholar 

  45. Salim N, Moore C, Silikas N, Satterthwaite J, Rautemaa R. Chlorhexidine is a highly effective topical broad-spectrum agent against Candida spp. Int J Antimicrob Agents. 2013;41:65–9.

    CAS  Article  PubMed  Google Scholar 

  46. Razzaghi-Abyaneh M, Sadeghi G, Zeinali E. Species distribution and antifungal susceptibility of Candida spp. isolated from superficial candidiasis in outpatients in Iran. J Mycol Med. 2014;24:e43–50.

    CAS  Article  PubMed  Google Scholar 

  47. Jewtuchowicz VM, Brusca MI, Mujica MT. Subgingival distribution of yeast and their antifungal susceptibility in immunocompetent subjects with and without dental devices. Acta Odontol Latinoam. 2007;20:17–22.

    PubMed  Google Scholar 

  48. Brito GN, Inocencio AC, Querido SM, Jorge AO, Koga-Ito CY. In vitro antifungal susceptibility of Candida spp. oral isolates from HIV-positive patients and control individuals. Braz Oral Res. 2011;25:28–33.

    Article  PubMed  Google Scholar 

  49. Ito CY, de Paiva Martins CA, Loberto JC, dos Santos SS, Jorge AO. In vitro antifungal susceptibility of Candida spp. isolates from patients with chronic periodontitis and from control patients. Braz Oral Res. 2004;18:80–4.

    Article  PubMed  Google Scholar 

  50. Moran GP, Sullivan DJ, Henman MC. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother. 1997;41:617–23.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Marcos-Arias C, Eraso E, Madariaga L, Carrillo-Muñoz AJ, Quindos G. In vitro activities of new triazole antifungal agents, posaconazole and voriconazole, against oral Candida isolates from patients suffering from denture stomatitis. Mycopathologia. 2012;173:35–46.

    CAS  Article  PubMed  Google Scholar 

  52. Pfaller MA, Rhomberg PR, Messer SA, Jones RN, Castanheira M. Isavuconazole, micafungin, and 8 comparator antifungal agents susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. Diagn Microbiol Infect Dis. 2015;82:303–13.

    CAS  Article  PubMed  Google Scholar 

  53. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J Clin Microbiol. 2008;46(2):551–9.

    CAS  Article  PubMed  Google Scholar 

  54. Smiline GA, Pandi SK, Hariprasad P, Raguraman R. A preliminary study on the screening of emerging drug resistance among the caries pathogens isolated from carious dentine. Indian J Dent Res. 2012;23:26–30.

    Article  PubMed  Google Scholar 

  55. Niimi M, Firth NA, Cannon RD. Antifungal drug resistance of oral fungi. Odontology. 2010;98:15–25.

    CAS  Article  PubMed  Google Scholar 

  56. Arikan S, Ostrosky-Zeichner L, Lozano-Chiu M. In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolates. J Clin Microbiol. 2002;40:1406–12.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  57. Quindós G, Carrillo-Muñoz AJ, Ruesga MT, Alonso-Vargas R, Miranda Y, Tur-Tur C, Rubio M, Wallace TL, Cossum PA, Martín-Mazuelos E, Cisterna R, Pontón J. In vitro activity of a new liposomal nystatin formulation against opportunistic fungal pathogens. Eur J Clin Microbiol Infect Dis. 2000;19:645–8.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Cristina Marcos-Arias is recipient of a grant from Fundación ONCE (« Oportunidad al Talento ») and Fondo Social Europeo. Elena Eraso and Guillermo Quindós have received grant support from Consejería de Educación, Universidades e Investigación (GIC15 78-IT-990-16 and GIC12 210-IT-809-13) and Departamento de Industria, Comercio y Turismo (S-PE13UN121) of Gobierno Vasco-Eusko Jaurlaritza, Fondo de Investigación Sanitaria (FIS PI11/00203), and UPV/EHU (UFI 11/25). Xabier Marichalar-Mendia, María Ángeles Echebarria-Goicouria, and José Manuel Aguirre-Urizar have received grant support from Consejería de Educación, Universidades e Investigación (GIC12 IT-809-13) of Gobierno Vasco-Eusko Jaurlaritza.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Guillermo Quindós.

Ethics declarations

Conflict of interest

In the past 5 years, Elena Eraso has received grant support from Astellas Pharma, and Pfizer SLU. Guillermo Quindós has received grant support from Astellas Pharma, Gilead Sciences, Pfizer SLU, Schering Plough and Merck Sharp and Dohme. He has been an advisor/consultant to Merck Sharp and Dohme, and has been paid for talks on behalf of Abbvie, Astellas Pharma, Esteve Hospital, Gilead Sciences, Merck Sharp and Dohme, Pfizer SLU, and Schering Plough. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

De-la-Torre, J., Ortiz-Samperio, M.E., Marcos-Arias, C. et al. In Vitro Antifungal Susceptibility of Oral Candida Isolates from Patients Suffering from Caries and Chronic Periodontitis. Mycopathologia 182, 471–485 (2017). https://doi.org/10.1007/s11046-017-0112-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11046-017-0112-1

Keywords

  • Antifungal susceptibility
  • Oral
  • Candida
  • Caries
  • Chronic periodontitis
  • Amphotericin B
  • Nystatin
  • Miconazole
  • Fluconazole
  • Itraconazole
  • Voriconazole
  • Posaconazole